Overview

A Study of the Efficacy and Safety of Upadacitnib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies

Status:
Active, not recruiting

Trial end date:
2022-02-02

Target enrollment:

Participant gender:

Summary

The objective of this study is to evaluate the efficacy and safety of upadacitinib compared to placebo as induction therapy in participants with moderately and severely active Crohn's disease (CD).

Phase:

Phase 3

Details

Lead Sponsor:

AbbVie

Treatments:

Upadacitinib